"The Waiting is the Hardest Part: Does Longer Patent Pendency Mean More Valuable Patents?" 16 NW. J. TECH. & INTELL. PROP. 189 (2019).
Co-Author, “Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2- Receptor D2-Biased Agonist,” Journal of Medicinal Chemistry (February 2017).
Co-Author, “Synthesis and Pharmacological Characterization of Novel trans- Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R),” Journal of Medicinal Chemistry (February 2017).
Co-Author, “Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor,” Journal of Medicinal Chemistry (January 2017).
Co-Author, “Novel and High Affinity 2- [(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors,” Journal of Medicinal Chemistry (December 2016).
Co-Author, “Highly selective dopamine D3 (D3R) receptor antagonists and partial agonists based on eticlopride and the D3R crystal structure: new leads for opioid dependence treatment,” Journal of Medicinal Chemistry (August 2016).
Co-Author, “Evidence for Non-Canonical Neurotransmitter Activation: Norepinephrine as a Dopamine D2-like Receptor Agonist,” Molecular Pharmacology (April 2016).
Memberships & Affiliations
Admissions & Qualifications
- 2019, Illinois
- Registered to practice before the United States Patent and Trademark Office
- United States District Court for the Northern District of Illinois
- Northwestern Pritzker School of LawJ.D.cum laude2019
Northwestern Journal of Technology and Intellectual Property
- Washington University in St. LouisB.A., Chemistry-Biochemistry2014